Skip to Main Content.
Site navigation
Fidelity.com Home
  • Customer Service
  • Profile
  • Open an Account
  • Virtual Assistant
  • Log In
  • Customer Service
  • Profile
  • Open an Account
  • Virtual Assistant
  • Log Out
  • Accounts & Trade
    • Portfolio Log In Required
    • Portfolio
    • AccountPositions Log In Required
    • AccountPositions
    • Trade Log In Required
    • Trade
    • Trading Dashboard Log In Required
    • Trading Dashboard Log In Required
    • Active Trader Pro
    • Transfers
    • Cash Management Log In Required
    • Cash Management
    • Bill Pay Log In Required
    • Bill Pay
    • Full View Log In Required
    • Full View
    • Security Settings Log In Required
    • Security Settings
    • Account Features Log In Required
    • Account Features
    • Statements Log In Required
    • Statements
    • Fidelity Alternative Investments Program Log In Required
    • Tax Forms & Information
    • Retirement Distributions Log In Required
    • Fidelity Rewards+registered trademark Log In Required
    • Fidelity Rewards+registered trademark Log In Required
    • New Account Checklist Log In Required
    • Lending Solutions-Line of Credit Log In Required
    • Refer a Friend
  • Planning & Advice
    • What We Offer
    • Build Your Plan
    • My Goals
    • Financial Basics
    • Building Savings
    • Robo Investing Plus Financial Advice
    • Wealth Management
    • Find an advisor
    • Retirement
    • Life Events
    • Saving & Investing for a Child
    • Charitable Giving
  • News & Research
    • News
    • Wealth Management Insights
    • Watch List Log In Required
    • Quotes
    • Quotes
    • Alerts Log In Required
    • Mutual Funds
    • Stocks
    • Fixed Income, Bonds & CDs
    • ETFs
    • Options
    • Markets & Sectors
    • IPOs
    • Annuities
    • Learning Center
    • Notebook
    • Notebook
  • Investment Products
    • Mutual Funds
    • Retirement & IRAs
    • Stocks and Trading
    • Crypto
    • Direct Indexing
    • Fixed Income, Bonds & CDs
    • ETFs
    • Options
    • Sustainable Investing
    • Cash Management & Credit Cards
    • Managed Accounts
    • 529 College Savings
    • Health Savings Accounts
    • Annuities
    • Life Insurance & Long Term Care
  • Why Fidelity
    • The Fidelity Advantage
    • Planning & Advice
    • Trading
    • Straightforward Pricing
    • Insights & Tools
    • Security & Protection
    • Marketplace Solutions
    • About Fidelity
    • Careers
  • Customer Service
  • Profile
  • Open an Account
  • Virtual Assistant
  • Log In
  • Customer Service
  • Profile
  • Open an Account
  • Virtual Assistant
  • Log Out
Content and data provided by various third parties and Fidelity − Terms of Use
  • Research >
  • Stocks >
  • News & Events >

Stock Details


  • Snapshot
  • Detailed Quote
  • Advanced Chart &
    Technical Analysis Opens in New Window
  • News & Events
  • Compare
  • Analyst Opinions
  • Research Reports
  • Key Statistics
  • Earnings
  • Dividends
  • Ownership & Insiders
  • Financial Statements
  • SEC Filings

RELATED RESOURCES

  • Stock Research Overview
  • Stock Screeners
  • Markets & Sectors
  • Fidelity Learning Center Opens in New Window
Print Format
Change Text Size:
  • Default text sizeA
  • Larger text sizeA
  • Largest text sizeA

Horizon Therapeutics plc Launches #RAREis Global Advocate Grant Program to Support the Rare Disease Community

BY Business Wire
— 4:05 PM ET 05/02/2022

DUBLIN--(BUSINESS WIRE)-- Horizon Therapeutics plc (HZNP) today announced the launch of the #RAREis Global Advocate Grant, a new program designed to support the rare disease community by providing financial assistance to U.S. and global patient advocacy groups working to advance, educate and address the needs of the community.

With more than 7,000 known rare diseases impacting over 400 million people worldwide, the need for rare disease innovation is significant. The #RAREis Global Advocate Grant is committed to making a positive difference for the rare disease community.

In 2022, up to 30 patient advocacy groups will be eligible to receive a one-time $5,000 grant. In order to qualify, groups will be required to submit a request. Horizon will manage the application process, selection and distribution of the grants. Applications will be evaluated based on the needs outlined by each patient advocacy organization that applies, as well as the potential impact of the grant. For more information and to apply, visit RAREiscommunity.com/Grant. Applications are open from Monday, May 2 to Friday, June 3, 2022. Recipients will be announced in June and grants will be provided in July 2022.

“Horizon’s approach is to listen, learn and understand the challenges of the rare disease community, ultimately working to help patients get better educated, engage with each other and seek the best possible care,” said Matt Flesch, vice president, communications and patient advocacy, Horizon. “Finding new ways to support the community is the driving force behind what we do each day, and the #RAREis Global Advocate Grant will help many smaller rare non-profit organizations better educate and engage their communities.”

The #RAREis Global Advocate Grant is the latest expansion of Horizon’s #RAREis™ program, which is committed to improving the experience of living with a rare disease, by providing support to many organizations that offer crucial programs and services for people living with rare diseases. Other #RAREis programs include the #RAREis Playlist, #RAREis Adoption Fund, and #RAREis Scholarship.

About #RAREis

In February of 2017, Horizon launched the #RAREis program aimed at elevating the voices, faces and experiences of people living with rare diseases, as well as highlight programs and resources for the rare disease community. The program is anchored by an Instagram page and website that showcases photos and stories of people touched by rare disease and captures elements of their patient, caregiver or advocate experience. To learn more, visit the #RAREis Instagram and Facebook page and visit the website at www.RAREisCommunity.com.

About Horizon

Horizon is focused on the discovery, development and commercialization of medicines that address critical needs for people impacted by rare, autoimmune and severe inflammatory diseases. Our pipeline is purposeful: We apply scientific expertise and courage to bring clinically meaningful therapies to patients. We believe science and compassion must work together to transform lives. For more information on how we go to incredible lengths to impact lives, visit www.horizontherapeutics.com and follow us on Twitter, LinkedIn, Instagram and Facebook.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220502005133/en/

Source: Horizon Therapeutics plc (HZNP)

More HZNP News

  • Horizon Therapeutics' Inebilizumab Scores European Approval For Spinal Cord Inflammation
    Benzinga - 1:09 PM ET 05/02/2022
  • BRIEF-Horizon Therapeutics Says Received European Commission Approval Of Uplizna
    Reuters - 1:05 AM ET 05/02/2022
  • Horizon Therapeutics plc Receives European Commission (EC) Approval of UPLIZNA® (inebilizumab) for the Treatment of Adults With Neuromyelitis Optica Spectrum Disorder (NMOSD)
    Business Wire - 1:00 AM ET 05/02/2022
Fidelity Investments. Copyright 1998–2022 FMR LLC. 
All rights reserved. 

  • Terms of Use|
  • Privacy|
  • Security|
  • Site Map 
Close